A warehouse-based approach to designing personalized peptide vaccines for chronic lymphocytic leukemia proved feasible and safe in a Phase II trial, though immune responses were limited by prior chemotherapy.
100% vaccine design feasibilityPersonalized peptide vaccines were successfully assembled from a pre-manufactured warehouse for all 26 CLL patients based on their individual HLA profiles
What the researchers found
The warehouse-based immunopeptidome-guided vaccine design was feasible for all 26 CLL patients, proving the personalized approach works at a practical level. Vaccination was well-tolerated, with local injection site reactions being the most common adverse event. However, only a few patients showed vaccine-induced T cell responses, attributed to immunosuppression from prior immuno-chemotherapy and the lack of a sufficiently potent adjuvant.
A follow-up trial (NCT04688385) is now combining this warehouse approach with a more potent adjuvant and BTK inhibitor therapies that support T cell function, addressing the key limitations identified.
Why it matters
Personalized cancer vaccines have been limited by the time and cost of manufacturing custom peptides for each patient. This warehouse approach solves a major logistical problem: by pre-making a library of cancer-associated peptides, personalized vaccines can be assembled quickly for any patient. While the immune responses were disappointing in this immunocompromised population, the proof of feasibility is a significant advance for the field.
How the study worked
Phase II clinical trial (NCT02802943) enrolling 26 CLL patients in at least partial remission after 6 months of first-line immuno-chemotherapy. Each patient received a personalized vaccine assembled from a pre-manufactured peptide warehouse containing immunopeptidome-defined CLL-associated peptides, tailored to the patient's HLA type. Primary endpoint was immunogenicity (T cell responses), with secondary endpoints of safety and minimal residual disease (MRD) response.
What this study cannot tell us
The primary limitation was the weak immune responses observed, attributed to patients' immunocompromised state after chemotherapy. The study lacked a control arm. Only patients in partial remission or better were enrolled, so the approach wasn't tested in patients with active disease. The peptide warehouse concept, while feasible, requires validation of clinical efficacy in a controlled trial with optimized adjuvants and less immunosuppressed patients.
How to read the evidence
This is a Phase II clinical trial published in Frontiers in Immunology. While it provides human clinical data and establishes feasibility, the single-arm design without controls and limited immunogenicity results temper the evidence strength. It is primarily a proof-of-concept study.
When this study was published
Published in 2024, this is a recent report from a trial registered in 2016. A follow-up trial (NCT04688385) with improved design is ongoing, so this represents an evolving program.
The bigger picture
Personalized peptide vaccines are one of the most promising frontiers in cancer immunotherapy. The immunopeptidome-guided warehouse concept addresses a critical bottleneck — scalability. If successful with improved adjuvants, this approach could be applied across cancer types, making personalized vaccination a practical clinical reality rather than a research curiosity.
Questions still open
- Will the follow-up trial with a potent adjuvant and BTK inhibitor support show improved T cell responses in CLL patients?
- Can the warehouse-based peptide vaccine approach be scaled to other cancer types with similarly mapped immunopeptidomes?
- What is the optimal timing for peptide vaccination relative to chemotherapy to maximize immune response?
Common questions
What is a 'warehouse-based' peptide vaccine?
Why didn't the vaccine produce strong immune responses?
Read the original research
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.
Frontiers in immunology, 15, 1482715
Citation
Heitmann, Jonas S; Jung, Susanne; Wacker, Marcel; Maringer, Yacine; Nelde, Annika; Bauer, Jens; Denk, Monika; Hoenisch-Gravel, Naomi; Richter, Marion; Oezbek, Melek T; Dubbelaar, Marissa L; Bilich, Tatjana; Pumptow, Marina; Martus, Peter; Illerhaus, Gerald; Denzlinger, Claudio; Steinbach, Francesca; Aulitzky, Walter-Erich; Müller, Martin R; Dörfel, Daniela; Rammensee, Hans-Georg; Salih, Helmut R; Walz, Juliane S. (2024). Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.. Frontiers in immunology, 15, 1482715. https://doi.org/10.3389/fimmu.2024.1482715